PF-06372865, with the CAS number 1614245-70-3, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is classified as a small molecule and is known to act as a selective inhibitor of certain protein kinases, which are crucial in various cellular signaling pathways. The compound's structure typically features a complex arrangement of functional groups that contribute to its biological activity and specificity. In preclinical studies, PF-06372865 has shown promise in modulating pathways associated with diseases such as cancer and inflammatory disorders. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), are essential for determining its efficacy and safety profile. As with many investigational drugs, ongoing research aims to elucidate its mechanism of action, optimize its therapeutic potential, and assess its side effects in clinical settings. Overall, PF-06372865 represents a significant area of interest in drug development, particularly in the context of targeted therapies.

PF-06372865

1614245-70-3: PF-06372865, with the CAS number 1614245-70-3, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is classified as a small molecule and is known to act as a selective inhibitor of certain protein kinases, which are crucial in various cellular signaling pathways. The compound's structure typically features a complex arrangement of functional groups that contribute to its biological activity and specificity. In preclinical studies, PF-06372865 has shown promise in modulating pathways associated with diseases such as cancer and inflammatory disorders. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), are essential for determining its efficacy and safety profile. As with many investigational drugs, ongoing research aims to elucidate its mechanism of action, optimize its therapeutic potential, and assess its side effects in clinical settings. Overall, PF-06372865 represents a significant area of interest in drug development, particularly in the context of targeted therapies.

Darigabat

<p>Darigabat (PF-06372865) is a GABAA receptor modulator with anxiolytic activity that inhibits α2, α1 PAM, and α2 PAM.</p>

<p>Positive allosteric modulator of GABA(A) receptor</p>

CAS 1614245-70-3

PF-06372865

Darigabat

Ref: 54-BUP21642

Darigabat

Ref: TM-T16489

PF 06372865

Ref: 3D-BP166580